PSI-6130
id:
psi-6130-296-6165144
title:
PSI-6130
text:
PSI-6130 is an experimental treatment for hepatitis C. PSI-6130 is a member of a class of antiviral drugs known as nucleoside polymerase inhibitors that was created by chemist Jeremy L. Clark. Specifically, PSI-6130 inhibits the hepatitis C virus RNA dependant RNA polymerase called NS5B. PSI-6130 is currently being developed by Hoffmann–La Roche as a 3',5'-diisobutyrl ester prodrug, R7128. R7128 is part of the combination of all-oral agents clinical trial known as INFORM-1.
brand slug:
wiki
category slug:
encyclopedia
description:
Chemical compound
original url:
https://en.wikipedia.org/wiki/PSI-6130
date created:
date modified:
2024-03-29T02:12:39Z
main entity:
{"identifier":"Q7120654","url":"https://www.wikidata.org/entity/Q7120654"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/c/cb/PSI-6130.svg","width":512,"height":577}
fields total:
13
integrity:
15